ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 145,48
-0,11%
Dow Jones
43 428,02
-1,69%
DAX
22 481,49
0,98%
Brent Oil
74,205
0,13%
Bitcoin
95 646,69
-0,65%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Akari Therapeutics PLC (AKTX)

  7. Akari Therapeutics PLC (AKTX) Actualités

AKTX

Akari Therapeutics (AKTX)

Akari Therapeutics PLC
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AKTX
DateHeureSourceTitreSymboleSociété
19/02/202515h00GlobeNewswire Inc.Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceNASDAQ:AKTXAkari Therapeutics PLC
14/02/202523h00Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
07/02/202522h30Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
03/02/202514h00GlobeNewswire Inc.Akari Therapeutics Joins Webull Corporate Connect Service PlatformNASDAQ:AKTXAkari Therapeutics PLC
13/01/202514h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
13/01/202514h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
26/12/202422h30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
18/12/202414h51GlobeNewswire Inc.Akari Therapeutics Announces Key Leadership AppointmentsNASDAQ:AKTXAkari Therapeutics PLC
16/12/202415h05GlobeNewswire Inc.Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial OfficerNASDAQ:AKTXAkari Therapeutics PLC
06/12/202422h00Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
19/11/202422h48Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AKTXAkari Therapeutics PLC
15/11/202422h05Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:AKTXAkari Therapeutics PLC
15/10/202414h51Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:AKTXAkari Therapeutics PLC
11/10/202422h52Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:AKTXAkari Therapeutics PLC
09/10/202422h27Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
16/09/202422h05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AKTXAkari Therapeutics PLC
16/09/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AKTXAkari Therapeutics PLC
13/09/202423h30Edgar (US Regulatory)Form S-4 - Registration of securities, business combinationsNASDAQ:AKTXAkari Therapeutics PLC
06/09/202423h23Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:AKTXAkari Therapeutics PLC
23/08/202422h30Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
20/06/202413h30Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
18/06/202422h15Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:AKTXAkari Therapeutics PLC
03/06/202422h21Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AKTXAkari Therapeutics PLC
15/03/202417h53PR Newswire (US)Kuehn Law Encourages VIVK, MINM, SDPI, and AKTX Investors to Contact Law FirmNASDAQ:AKTXAkari Therapeutics PLC
09/01/202423h25Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:AKTXAkari Therapeutics PLC
01/12/202314h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AKTXAkari Therapeutics PLC
20/10/202322h29Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:AKTXAkari Therapeutics PLC
20/10/202322h23Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:AKTXAkari Therapeutics PLC
12/10/202322h43Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AKTXAkari Therapeutics PLC
07/06/202312h03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AKTXAkari Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:AKTX

Dernières Valeurs Consultées

FTSE
UKX
FTSE 100
NASDAQ
NVDA
NVIDIA
EU
PX4
SBF 120
EU
VIV
Vivendi
COIN
XRPUSD
Ripple
EU
CS
Axa
NYSE
DIS
Walt Disney
NYSE
KO
Coca Cola
EU
AI
Air Liquide
EU
RNO
Renault
EU
BEL20
Bel 20
NASDAQ
AAPL
Apple
EU
BNP
BNP Paribas
EU
MC
Lvmh Moet Hennessy Louis...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces